Vernon Hartz

411 total citations
16 papers, 273 citations indexed

About

Vernon Hartz is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Vernon Hartz has authored 16 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 3 papers in Surgery and 2 papers in Molecular Biology. Recurrent topics in Vernon Hartz's work include Cardiac electrophysiology and arrhythmias (10 papers), Cardiac Arrhythmias and Treatments (7 papers) and ECG Monitoring and Analysis (4 papers). Vernon Hartz is often cited by papers focused on Cardiac electrophysiology and arrhythmias (10 papers), Cardiac Arrhythmias and Treatments (7 papers) and ECG Monitoring and Analysis (4 papers). Vernon Hartz collaborates with scholars based in United States, United Kingdom and Canada. Vernon Hartz's co-authors include Elizabeth A. Hahn, Jay W. Mason, Gregory M. Marcus, Michael J. Reiter, Anthony C. Caruso, Brian Olshansky, A Herskowitz, Lisa A. Mendes, John B. OʼConnell and Igor F. Palacios and has published in prestigious journals such as Circulation, European Heart Journal and The American Journal of Cardiology.

In The Last Decade

Vernon Hartz

14 papers receiving 258 citations

Peers

Vernon Hartz

CCM

SURGE

EPIDE

Sandrine Brette France

Šime Manola Croatia

Ashish Nabar Netherlands

Dalius Vitkus Lithuania

G. J. Kootstra Netherlands

Chih-Ping Hsia Taiwan

Michel Scemama France

Giulia Laterra Italy

Kitty Cheung Hong Kong

Jasmine Gratton United Kingdom

Sandrine Brette France

Vernon Hartz

203 ×1.0

CCM

43 ×0.7

SURGE

21 ×0.8

23 ×1.1

EPIDE

4 ×0.3

Citations per year, relative to Vernon Hartz Vernon Hartz (= 1×) peers Sandrine Brette

Countries citing papers authored by Vernon Hartz

Since Specialization

Citations

This map shows the geographic impact of Vernon Hartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vernon Hartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vernon Hartz more than expected).

Fields of papers citing papers by Vernon Hartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vernon Hartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vernon Hartz. The network helps show where Vernon Hartz may publish in the future.

Co-authorship network of co-authors of Vernon Hartz

This figure shows the co-authorship network connecting the top 25 collaborators of Vernon Hartz. A scholar is included among the top collaborators of Vernon Hartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vernon Hartz. Vernon Hartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Matsumori, Akira, Toshio Shimada, Eiji Nakatani, et al.. (2020). Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis. Clinical Immunology. 217. 108455–108455. 12 indexed citations

Thomson, Cynthia A., Ellen Graver, Kelly A. Jackson, et al.. (2007). Cruciferous Vegetable Intake Questionnaire Improves Cruciferous Vegetable Intake Estimates. Journal of the American Dietetic Association. 107(4). 631–643. 30 indexed citations

Jacobs, Elizabeth T., Anna R. Giuliano, Denise J. Roe, et al.. (2003). Dietary change in an intervention trial of wheat bran fiber and colorectal adenoma recurrence. Annals of Epidemiology. 14(4). 280–286. 2 indexed citations

Olshansky, Brian, et al.. (2000). Location of death (in-hospital or out-of-hospital) and type of death (arrhythmic, nonarrhythmic, noncardiac) after inducible sustained ventricular tachyarrhythmias after syncope, sustained ventricular tachycardia, or nonfatal cardiac arrest (the ESVEM trial). The American Journal of Cardiology. 86(8). 846–851. 7 indexed citations

Mendes, Lisa A., Michael H. Picard, GW Dec, et al.. (1999). Ventricular remodeling in active myocarditis. American Heart Journal. 138(2). 303–308. 38 indexed citations

Olshansky, Brian, et al.. (1999). Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. American Heart Journal. 137(5). 878–886. 33 indexed citations

Sharma, Param, Peter Ott, Vernon Hartz, Jay W. Mason, & Gregory M. Marcus. (1998). Risk Factors for Tachycardia Events Caused by Antiarrhythmic Drugs: Experience From the ESVEM Trial. Journal of Cardiovascular Pharmacology and Therapeutics. 3(4). 269–274. 5 indexed citations

Mann, David E., Vernon Hartz, Elizabeth A. Hahn, & Michael J. Reiter. (1997). Effect of Reproducibility of Baseline Arrhythmia Induction on Drug Efficacy Predictions and Outcome in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial fn1fn1This study was supported in part by Grant RO-1-HL34071 from the National Heart, Lung, and Blood Institute, and Grant M01-RR00064 from the National Center for Research Resources, Bethesda, Maryland; and by Bristol-Myers Squibb Company, Princeton, New Jersey; Knoll Pharmaceutical Company, Whippany, New Jersey; Boehringer-Ingelheim, Ridgefield, Connecticut; Parke-Davis, Morris Plains, New Jersey; and Ciba-Geigy, Summit, New Jersey.. The American Journal of Cardiology. 80(11). 1448–1452. 1 indexed citations

Reiter, Michael J., Labros A. Karagounis, David E. Mann, et al.. (1997). Reproducibility of Drug Efficacy Predictions by Holter Monitoring in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial. The American Journal of Cardiology. 79(3). 315–322. 1 indexed citations

10.

Reiffel, James A., Elizabeth A. Hahn, Vernon Hartz, & Michael J. Reiter. (1997). Sotalol for Ventricular Tachyarrhythmias: Beta-Blocking and Class III Contributions, and Relative Efficacy Versus Class I Drugs After Prior Drug Failure. The American Journal of Cardiology. 79(8). 1048–1053. 19 indexed citations

11.

Hlatky, Mark A., Derek Boothroyd, Iain M. Johnstone, et al.. (1997). Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias. Journal of Clinical Epidemiology. 50(2). 185–193. 8 indexed citations

12.

Caruso, Anthony C., Gregory M. Marcus, Elizabeth A. Hahn, Vernon Hartz, & Jay W. Mason. (1997). Predictors of Arrhythmic Death and Cardiac Arrest in the ESVEM Trial. Circulation. 96(6). 1888–1892. 45 indexed citations

13.

Reiffel, James A., Michael J. Reiter, Roger A. Freedman, et al.. (1996). Influence of holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. Progress in Cardiovascular Diseases. 38(5). 359–370. 10 indexed citations

14.

Hahn, Elizabeth A., Vernon Hartz, Thomas E. Moon, et al.. (1995). The Myocarditis Treatment Trial: design, methods and patient enrolment. European Heart Journal. 16(suppl O). 162–167. 40 indexed citations

15.

Reiter, Michael J., et al.. (1995). Significance and Incidence of Concordance of Drug Efficacy Predictions by Holter Monitoring and Electrophysiological Study in the ESVEM Trial. Circulation. 91(7). 1988–1995. 13 indexed citations

16.

Omoigui, Nowamagbe A., Gregory M. Marcus, Jay W. Mason, et al.. (1995). Cost of Initial Therapy in the Electrophysiological Study Versus ECG Monitoring Trial (ESVEM). Circulation. 91(4). 1070–1076. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact